SOURCE: Medifocus, Inc.

Medifocus, Inc.

March 18, 2013 11:36 ET

Medifocus, Inc. Announces Completion of Shares for Debt Transaction

Transaction Reflects Management and Suppliers' Confidence in Company

COLUMBIA, MD and TORONTO--(Marketwire - Mar 18, 2013) - Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the completion of the share for debt transaction originally announced January 29, 2013. The Company issued today an aggregate of 1,090,000 common shares at a deemed price of $0.25 per common share to settle an aggregate of $272,500 of debt representing unpaid salary ($210,000) and amounts due to service providers ($62,500). 

All of the common shares issued in connection with the shares for debt transaction are subject a hold period expiring July 15, 2013.

Augustine Cheung, CEO of Medifocus, commented, "These obligations were accrued at a time when the Company was somewhat cash constrained. It is an indication of confidence in the Company's future that management and vendors choose to convert their accrued obligations into stock in the Company."

About Medifocus, Inc.

Medifocus develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia ("BPH"). With the recent acquisition of Prolieve®, Medifocus now owns a revenue generating commercial BPH treatment product targeting the $8 billion BPH drug therapy market and generating cash flow to support the development and commercialization of other catheter based or Adaptive Phased Array (APA) based focused heat systems for targeted thermotherapy of surface, subsurface and deep seated localized and regional cancers.

The Company owns two technology platforms with comprehensive US and international patent protection: 1: The Endo-thermotherapy Platform-from which Prolieve was developed can potentially used to treat cancers in prostate, rectal, cervical and esophageal, and 2: The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is currently in pivotal Phase-III clinical trials. Please visit www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus's future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Company Contact:
    Dr. Augustine Y. Cheung
    President and CEO
    Medifocus, Inc.
    Tel: 410-290-5734
    acheung@medifocusinc.com

    Investor Relations Contact:
    Robert Giordano
    Consulting for Strategic Growth 1
    T: 917-327-3938
    rgiordanonyc@gmail.com